Ropes & Gray has represented CAMP4 Therapeutics in a $30 million underwritten offering of common stock. The transaction priced on Dec. 18 and closed Dec. 19. Ropes & Gray advised CAMP4 on a $100 million private placement in September.
CAMP4 is a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases.
The team was led by capital markets partner Tom Danielski and capital markets counsel Lisa Folkerth.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.